Archive | Redefining Every Stage Investments (RESI) RSS feed for this section

Know Your Competitive Landscape

14 Apr

By Greg Mannix, Vice President International Business Development, General Manager Europe, LSN

Do you know the players in your field that are developing similar technologies, or different technologies for the same application? Do you understand how your technology compares to those potential competitors? These are issues investors will want to see you have a grasp on, so having a clear vision of your Competitive Landscape will add a lot of value when you are pitching for investment.

Life Science Nation (LSN) offers valuable resources to early-stage companies as they seek funding and develop their strategies to grow and progress. To track your competitive landscape, LSN has a powerful business development database that tracks more than 60,000 companies across all the verticals of the life sciences and all stages of development. In just a few clicks, you can see your own competitive landscape.

Once you’ve seen the competitive landscape, it’s important to understand how to communicate your unique value. We can also help you understand and effectively communicate this, extracted in part from your better picture of the Competitive Landscape, through LSN’s Branding & Messaging consulting services. Experts will work with you to develop optimal marketing collateral for you to use in your communication with investors and partners, increasing your odds of success. Hear from Reglagene CEO Richard Austin on how he learned to tell his company story and how it impacted his early-stage fundraising.

Finally, you can put your enhanced market comprehension, communication skills and story to the test in the Innovator’s Pitch Challenge (IPC) at Digital RESI, June 7-9. The IPC is a fantastic showcase for founders who participate in a live Q&A from investors and strategic partners from different sectors in life science and healthcare. Investors frequently ask pitching founders about their unique value and market competition. A keen and well-communicated understanding of the competitive landscape shows investors that you don’t just function within an industry – you know it.

This knowledge can help you position yourself, not just accurately among competitors, but as someone who really knows their industry. To learn more about your competitive landscape or about any products or services mentioned, reach out to connect with LSN’s dedicated business development team.

Want to learn more? The Business Development team at Life Science Nation is available to answer questions and share additional details to help you meet your partnership goals!
International
East Coast (USA) & China
Midwest (USA)
& Canada
West Coast  (USA)
Alex
Greg Mannix
Vice President International Business Development
Book a Meeting
Email Me
Candice He
VP, Business Development & Global Investment Strategist
Book a Meeting
Email Me
Antoinette Lowre
Manager of Business Development
Book a Meeting
Email Me
Alexander Vassallo
Manager of Business Development
Book a Meeting
Email Me

Preparing to Pitch with the End in Mind

14 Apr

By Rory McCann, Marketing Manager & Conference Producer, LSN

Bold Therapeutics is a clinical-stage pharma startup developing and commercializing novel therapeutics to combat drug resistance in cancer and infectious disease. At Digital RESI March, Bold Therapeutics founder Russell McAllister met success at the Innovator’s Pitch Challenge (IPC) and is sharing his perspectives from preparation to pitch to follow-up conversations. If you’re actively fundraising or considering pitching at RESI, check out our conversation and learn how Russell leveraged, not only his company, but his own unique experience to stand out at RESI.

IPC applications are still live until Friday, April 29. Get your application in by Friday, April 15 to save on super early bird rates!

AI & Longevity at RESI

7 Apr

By Caitlin Dolegowski, Marketing Specialist, LSN

The Redefining Early Stage Investments (RESI) conference series proudly highlights active investors, early-stage founders, and industry leaders advancing drugs, devices, diagnostics, and digital health. RESI is unique in its focus on early-stage life science and healthcare, but in recent years, has gone even further to cut out space specifically for artificial intelligence (AI) and age-tech innovation. To do this, RESI conferences feature specialized content for startups and strategic partners in these industries through dedicated panels and pitch competitions.

Innovative advancements within these industries and a deep dive into insights around how to navigate the early-stage investment ecosystem specific to conversations happening in AI and Longevity arenas are a major addition and highlight at RESI. Panels provide discussions with investors, industry experts, entrepreneurs, and strategic partners answering questions about early-stage fundraising and age-tech and AI innovation.

View sample panel sessions from Digital RESI March:

LONGEVITY

Digital Health & Wellness
Silver-Tech Focusing on Preventative Care
According to the US Census Bureau, the 65+ population grew by 34% since 2010. These seniors are prioritizing preventative care and the market is responding with products and services focused on staying healthy, specifically those focused on daily exercise, diet, and other factors impacting independence and longevity. How can startups in this booming industry stand out to investors?

AI

Defining AI Investment
AI-Exclusive Investors Share Their Perspectives
Hear from leaders investing exclusively in AI products across drugs, devices, diagnostics, and digital health. Learn more about what AI-exclusive investors have to offer healthtech startups. Learn what entrepreneurs can gain from partnerships that understand their tech and how to take it to the next level.

The lens on age-tech and AI continues at our next conference, Digital RESI, June 7-9. The focus on these markets will include panel topics:

LONGEVITY

Tuesday, June 7 – 2PM EDT | The Neuroscience of Aging
Aging Impact on the Nervous System

Age-tech startups are addressing negative impacts of neurological aging, such as cognitive decline, dementia, and Alzheimer’s. The goal of many of these early-stage companies is to stimulate neurogenesis and enhance brain plasticity to combat these conditions.

Thursday, June 9 – 11 AM EDT – Age-Tech Care Management
Technology Improving the Lives of Older Adults

Older adults are looking to age-tech to provide freedom, medical access & adherence, safety, wellness and even companionship later in life. Age-tech allows seniors, and their caregivers make personalized choices about their own aging journeys. Hear from investors specializing in longevity innovation.

AI

Wednesday, June 8 – 11 AM EDT – AI vs. Life Science
Which Comes First in Early-Stage Investment?

How to prioritize tech-first vs. biology models? How can each model leverage their position in the industry and be successful in the early stage? How can startup founders balance the “bio” and “tech” and highlight their strengths to investors? What are some strategies to help fundraising executives target the right investors for their company and pivot their pitch to each?

Thursday, June 9 – 2 PM EDT – Team, Tech, & Traction in Early-Stage AI
Building Your Startup as a Triple Threat

Early-stage investors will take a chance on a team, tech, or traction. It’s rare to find all three in a company seeking Seed to Series B funding. This discussion will explore the value of each to help early-stage startups highlight their unique assets and improve their position in weaker areas.

Register by April 15 to save $300 with our Super Early Bird rates.

Top 10 Challenges for Startups Raising Capital and Seeking Licensing Deals

7 Apr

By Dennis Ford, Founder and CEO of Life Science Nation, Creator of the LSN Partnering Conference Series

Check out a recent list of the top challenges startups face when entering the early-stage fundraising arena. Each challenge is linked to an article tackling these and similar issues.

  1. Migrating from regional mindset to global partnering arena
  2. Understanding that deals take 9-18 months and identifying vehicles that can assist in partnering campaigns early
  3. Defining and understanding their competitive landscape
  4. Compiling a global target list (GTL) that is a fit for product and stage of development
  5. Understanding the cost of launching and executing a global partnering campaign ($60K-$90K)
  6. Developing branding and messaging that highlights unique company value that is clear, concise, and easy to understand
  7. Implementing a CRM to activate and organize global campaign, which includes ongoing curation of partner list, outreach initiatives, and tracks status and to-do list for all meetings
  8. Hitting the road with phone and email canvassing, as well as traveling to conferences to engage partners
  9. Learning the art of follow-up (99% of all startups fail here)
  10. Learning how to efficiently partner at a partnering conference

Life Science Nation is committed to facilitating well-fitting meetings between founders with innovative assets and the capital and channel partners who seek them. Join us for one of our free fundraising bootcamps to learn about the products and services we offer to the startup community in life science and healthcare.

Preparing to Pitch at RESI 
  • Alexander Vassallo, Manager, Business Development, Life Science Nation
The Innovator’s Pitch Challenge (IPC) is an opportunity for early-stage companies to gain additional exposure to conference attendees, pitch directly to a panel of relevant investors, and participate in a live Q&A session. This bootcamp will walk through the process of preparing your pitch materials and what to expect in a live pitch session, including frequently asked questions from investor judges.

Fundraising 101: Avoiding Pitfalls and Improving the Odds
  • Karen Deyo, Director, Investor Research, Israel Business Development, Life Science Nation
  • Candice He, Vice President, Business Development, Global Investment Strategist, Life Science Nation
This bootcamp is designed to help scientist-entrepreneurs navigate the world of fundraising. It starts out by debunking some commonly held misconceptions about early-stage startups and fundraising, followed by tips on how to improve your chances and increasing investor visibility.
Preparing to Pitch at RESI
  • Candice He, Vice President, Business Development, Global Investment Strategist, Life Science Nation
The Innovator’s Pitch Challenge (IPC) is an opportunity for early-stage companies to gain additional exposure to conference attendees, pitch directly to a panel of relevant investors, and participate in a live Q&A session. This bootcamp will walk through the process of preparing your pitch materials and what to expect in a live pitch session, including frequently asked questions from investor judges.
Strategies for Successful Partnering
  • Alexander Vassallo, Manager, Business Development, Life Science Nation
  • Joey Wong, Analyst, Investor Research, Hong Kong BD Life Science Nation
This bootcamp is a fan favorite with tried-and-true tips to make your partnering experience exceptional, letting your technology, product, and team take center-stage. Whether booking 1-on-1 meetings or pitching to a panel, these strategies will help you prioritize the details that make a difference in telling your story to potential investors and strategic partners.

Our Redefining Early Stage Investments (RESI) conference returns in a virtual format June 7-9. Register today and save $300 on super early bird rates by April 15!

Register-now-button-new

Hot Longevity Mandate: East Coast Based VC Fund

5 Apr

The firm is a New York based early-stage fund founded in 2019. The firm is affiliated with, but separate from, a New York based university, leveraging the network of schools and 70,000 + alumni network to

help their portfolio companies. The firm invests in technology-based companies in the pre-seed and seed stage, and while they prefer the companies have some revenue, they will invest in pre-revenue companies. The firm invests in several verticals, including Seniors and Tech, PropTech, Fintech, Cybersecurity, HealthTech and AI/ML. The firm does not invest in therapeutics or medical devices. The firm invests in North America and in Israel, with check size between $50-150K into rounds with a pre-money valuation of $2-10M.

Within HealthTech, the firm invests in Seniors and Tech and digital health. For digital health, the company is interested primarily in B2B models, but will invest in B2B2C as well. The firm has a special interest in Agetech, as one of the GPs is third generation senior living owner/operator.

The firm does not lead rounds, but is a very active investor alongside top-tier funds. Due to their strategic value, they are asked to serve in an advisory capacity. The firm prides itself on being a valued strategic partner. The firm will invest in new or seasoned entrepreneurs, who have assembled exceptional teams.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

Hot Longevity Mandate: West Coast Based VC Fund

5 Apr

The firm is based in San Francisco, CA, and has an additional office in Japan. The firm is investing from a new fund that closed in 2016. The firm generally invests in Series A equity rounds, and typically commits a total of $1-4 million over the course of an investment. The firm invests 70% of its capital in the USA and Israel, with the remaining 30% in Japan. Under certain circumstances, the firm will invest outside those regions.

The firm invests in advanced therapeutics, healthcare IT, novel (sensor based IoT) devices and diagnostics, and second generation tools and technologies in the biotech R&D/laboratory innovation field. The firm is open to any indication area, and has a particular interest in diseases that afflict the elderly including Alzheimer’s disease and cancer. The firm prefers to invest in technologies at an early stage of development.

The firm is interested in working with high quality management teams.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

Hot Longevity Mandate: UK-Based Family Office

5 Apr

The firm is an active early stage venture fund based in the UK and Switzerland. The team is composed of experienced professionals in funding, entrepreneurship and therapeutic development. The firm has historically invested in computational biology, next generation tools for protein analysis and cell and gene therapy manufacturing technologies. Majority of technologies in the firm’s portfolio are relating to oncology, but going ahead the firm will consider any indication, if they find technology compelling. Firm has invested primarily in the UK and is willing to consider companies based in the broader Europe and in Switzerland in particular.

The firm is especially interested in companies developing therapeutic approaches, such as state of the art cell therapies that need local manufacturing, cancer vaccines, precision oncology medicine and novel therapies for autoimmune diseases. Delin Ventures is primarily interested in early stage, pre-clinical breakthrough technologies seeking seed investment.

The firm takes an active role with the companies in which they invest. The firm frequently leads rounds, and supports and mentors the early stage companies, often either taking a board seat themselves or finding an expert to serve on the board. Apart of building companies, the firm is also interested in the investment in the existing companies, syndicating with other investors

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

← Older Entries
Newer Entries →